Skip to main content
  • Loading metrics

A Meta-analysis of the Effectiveness of Albendazole Compared with Metronidazole as Treatments for Infections with Giardia duodenalis



Metronidazole is the most commonly used drug for the treatment of giardiasis in humans. In spite of its therapeutic efficacy for giardiasis, low patient compliance, especially in children, side effects, and the emergence of metronidazole-resistant strains may restrict its use. Albendazole has been used to treat Giardia duodenalis infections in recent years. However, efficacy studies in vivo and in vitro have produced diverse results as to its effectiveness. A moderately benign side effect profile, combined with established efficacy against many helminths, renders it promising for treatment of giardiasis in humans.

Methodology and Principal Findings

We performed a search in the PubMed, Scopus, EMBASE, the ISI Web of Science, LILIACS, and Cochrane Controlled Trials Register for trials published before February 2010 as well as in references of relevant research and review articles. Eight randomized clinical trials (including 900 patients) comparing the effectiveness of albendazole with that of metronidazole were included in meta-analysis. After extracting and validating the data, the pooled risk ratio (RR) was calculated using an inverse-variance random-effects model. Albendazole was found to be equally as effective as metronidazole in the treatment of giardiasis in humans (RR 0.97; 95% CI, 0.93, 1.01). In addition, safety analysis suggested that patients treated with albendazole had a lower risk of adverse effects compared with those who received metronidazole (RR 0.36; 95% CI, 0.10, 1.34), but limitations of the sample size precluded a definite conclusion.


The effectiveness of albendazole, when given as a single dose of 400 mg/day for 5 days, was comparable to that of metronidazole. Patients treated with albendazole tended to have fewer side effects compared with those who took metronidazole. Given the safety, effectiveness, and low costs of albendazole, this drug could be potentially used as an alternative and/or a replacement for the existing metronidazole therapy protocols in the treatment of giardiasis in humans.

Author Summary

Giardiasis is one of the most common intestinal protozoal infections worldwide. Although metronidazole is the most common drug used to treat giardiasis in humans, its use is associated with a variety of side effects. Poor compliance and the emergence of metronidazole-resistant strains may restrict use of the drug. Albendazole is an orally administered broad-spectrum anthelmintic agent. The use of albendazole has fewer side effects than metronidazole. The anthelmintic has been used against Giardia duodenalis both in vivo and in vitro with different results. However, the current meta-analysis assessed the effectiveness and safety of albendazole compared with metronidazole for the treatment of giardiasis in humans. After searching different databases, eight comparative randomized clinical trials, including 900 patients, met our criteria and were selected for the current meta-analysis. Results showed that albendazole was as effective as metronidazole for the treatment of giardiasis in humans and people receiving the drug tended to have fewer side effects compared with those who received metronidazole. Given the safety, effectiveness, and low costs of albendazole, this drug may be considered a potential alternative and/or a replacement for the existing widely used metronidazole in the treatment of giardiasis in humans.


Giardiasis in humans, caused by the protozoan parasite Giardia duodenalis (syn. G. lamblia, G. intestinalis), is a common parasitic disease [1]. The prevalence of infection is commonly between 2–5% in the developed world and 20–30% in the developing and underdeveloped countries [2]. Infection is initiated by ingestion of cysts in contaminated drinking water and/or contaminated food [1]. Ingested cysts release trophozoites which colonize and replicate in the small intestine of the new host. G. duodenalis does not invade the epithelial or deeper layers of the mucosa and propagation takes place on the epithelial surface [3]. The outcomes of Giardia infections vary significantly and the majority of infections are self-limiting. Clinical manifestations range from a relatively asymptomatic phase marked by mild nutrient malabsorption, to an ephemeral or persistent acute stage, with steatorrhea, intermittent diarrhea, vomiting, malabsorption syndrome and weight loss, or to a subacute chronic phase that can mimic gallbladder or peptic ulcer disease [4], [5]. Infections in immunocompetent individuals are generally self-limited, suggesting the existence of effective host defense mechanisms against the parasite [6]. Different diagnostic methods are employed for the diagnosis of human giardiasis of which the most insensitive method, direct stool microscopy is used routinely in developing countries where the disease is endemic [5], [7].

Existing chemotherapy protocols recommend that patients should be treated if the parasite is found, irrespective of the presence or absence of acute symptoms [8]. However, some investigators question the usefulness of chemotherapy in infected people in endemic areas due to the extremely high rate of reinfection, as high as 90% in some studies [9], [10]. Treatment preferences vary among clinicians and in different locations. Several synthetic compounds (including metronidazole and other nitroimidazole derivates such as albendazole, mebendazole, furazolidone, tinidazole, ornidazole) are used in the treatment of giardiasis in humans. A single dose of tinidazole (2.0 g) has been shown to have a clinical efficacy of 80–100% in different clinical trials [11], [12] while the compliance is improved compared with other giardiasis treatments. However, the high cost of tinidazole may restrict its use in mass chemotherapy campaigns [13] in developing and underdeveloped countries (e.g. $18 to $32 for a single-dose of 2 g for the treatment of trichomoniasis). The most widely used treatment protocols employ metronidazole given 3 times per day for 3–5 days [8], [14], [15], [16]. Metronidazole is typically administered in doses of 250 mg 3 times a day for 5–7 days for adults and 15 mg/kg 3 times a day for 5–7 days in children. However, albendazole is typically given as a single dose of 400 mg/day for 3–5 days. In recent years, therapeutic failure of metronidazole, the first-line drug of choice in giardiasis in humans, has increasingly been reported from all around the world [17]. Metronidazole is prescribed widely for a wide range of non-parasitic infectious diseases; overusing metronidazole as a treatment option for parasitic infections may increase the chances of the development of clinically drug-resistant strains of Helicobacter pylori, an important cause of gastric cancer in humans [18]. Low compliance of patients with the current metronidazole therapy protocols, the emergence of the metronidazole-resistant strains of the parasite and other pathogens, and rapid reinfection of treated patients in the endemic areas are additional reasons for considering alternative therapies [19].

Treatment compliance is a key factor affecting the outcome of giardiasis. However, compliance has been neglected in the literature [20], and is therefore not part of the current analysis. In one report on metronidazole use in patients with giardiasis, treatment compliance was extremely poor because of missed doses, spillage, inaccurate measuring implements, and poor adherence to the prescribed frequency and duration of medication [21]. Common adverse reactions frequently reported with metronidazole include metallic taste, nausea, vomiting, diarrhea, and epigastric discomfort [20]. Moreover, its activity against the host's normal intestinal microflora; its contraindication for children, pregnant and breastfeeding women; and its carcinogenic and tumorigenic properties in animal models make it less than optimal for widespread use [8]. Finding safer drugs with less toxicity and more effective therapeutic properties and developing novel protocols (e.g fewer doses and shortened duration) to maximize the effects of existing drugs are, therefore, crucial for the field.

Albendazole has been used extensively for the treatment of a wide range of helminth parasites including hookworms, Ascaris lumbricoides, Trichuris trichiura, Echinococcus sp.[22] and Taenia sp. [23] with few side effects (reviewed by Keiser and Utzinger [24]). The mechanism of action of albendazole differs from that of metronidazole. While metronidazole affects electron transport of the parasite [25], it is believed that albendazole exerts its anti-giardial effects by interaction with tubulin of the Giardia cytoskeleton [26]. Albendazole also has overt giardiacidal activity in vitro [27], as well as being able to resolve infections in a mouse model of G. duodenalis infection [19], [26]. Using albendazole against giardiasis in humans could potentially augment mass treatment programs, which are part of helminth control campaigns, since most patients with Giardia are probably co-infected with other parasitic agents. Altogether, the evidence suggests that albendazole could be considered as a potential anti-giardial agent. Its lower toxicity, its relative insolubility and poor absorption from the gut, and its lack of significant effects on the intestinal microflora could make albendazole an ideal substitute for metronidazole. The aims of the current meta-analysis, therefore, were first to address the effectiveness and second to assess the safety of albendazole compared with metronidazole for the treatment of giardiasis in humans.


Data source and study selection

A literature search of the PubMed database (1966–February 2010), Scopus, EMBASE, the Cochrane Controlled Trials Register (issue 4, 2009), LILIACS and the ISI Web of Science for trials published before February 2010 was performed. The literature search used the following terms: “giardiasis”, “metronidazole”, and “albendazole.” The abstracts of all selected articles were read to identify the potentially eligible articles. A manual search was performed systematically using the authors' reference files and reference lists from original communications, selected books and review articles [8], [28]. Language restriction was not applied. The contents of abstracts or full-text manuscripts identified during our literature search were reviewed to determine whether they met the criteria for inclusion. For inclusion, a study had to allocate the study participants randomly to study groups (a prospective randomized clinical trial). Included studies had to compare the effectiveness of albendazole with that of metronidazole in the treatment of giardiasis.

Figure 1 summarizes the trial selection process. Our search identified twenty-nine articles for further consideration, of which only eight articles met the inclusion criteria. Major reasons for exclusion of studies were duplicate publications from which only one article was selected [29], [30], animal models of infections [19], [26], studies of veterinary importance [31], studies in vitro [32], single-arm studies with no randomized control groups [33], studies lacking a comparison between the effectiveness of albendazole with metronidazole [34], review articles [8], [28], studies with no clear randomization allocation procedure [35], studies using albendazole and metronidazole analogues [36] as well as the studies showing the synergistic effects between albendazole and/or metronidazole with other drugs [37], [38]. Conference proceedings and unpublished data were also not included. Included articles compared the effectiveness of albendazole with that of metronidazole in the treatment of giardiasis [29], [39][45]. Together these articles followed 900 patients presenting with symptomatic and/or asymptomatic G. duodenalis infections. Among these 900 treated patients, 452 (50.2%) individuals were treated with albendazole whereas 448 (49.8%) received metronidazole.

Figure 1. Flow diagram deciphering the article selection process for this meta-analysis study.

Individual searches do not add up to 56 as some of the same articles were retrieved by multiple search engines.

Data extraction and analysis

Data were extracted independently by two reviewers (SSM and SMS) from the eight randomized controlled trials [Table 1 and Table 2]. Discrepancies were resolved by discussion. Study characteristics recorded were as follows: 1) first author's name, year of publication and country of origin; 2) description of the population; 3) number of participants; 4) age and sex distribution of the participants; 5) number of participants in each arm; 6) clinical profile (symptomatic, asymptomatic infections); 7) the follow-up period; 8) the outcome measure; 9) study design; 10) type and dosage of the drugs; and 11) effectiveness range.

Table 1. Characteristics of the randomized controlled trials included in the meta-analysis.

Table 2. Follow-up, outcomes assessment and relative risk in the trials included in the meta-analysis.

The primary outcome measure was parasitological cure defined as the absence of parasites (trophozoites and/or cysts) in feces at the end of the treatment in at least two consecutive stool microscopy examinations. Parasitological cure was considered necessary in order to evaluate the effectiveness of the treatment. The secondary outcome measure, clinical cure, was defined as the global improvement of clinical symptoms, such as diarrhea, nausea/vomiting, transient abdominal pain and loss of appetite, at the end of the follow-up period.

Assessment of study quality

The quality of included reports was compared using the Jadad score which examines whether there is randomization, blinding, and information on dropouts/withdrawals from the study [46]. It also evaluates the appropriateness of randomization and blinding, if present. The quality scale ranges from 0 to 5 points with a low-quality report earning score of 2 or less. A study with a Jadad score ≥3 is considered to be of ample quality. The quality of parasitological diagnostic methods was assessed by the scoring system utilized by Zaat et al. [47]. This method evaluates whether techniques are sufficiently described and are adequate. Moreover, this method evaluates the reproducibility of the parasitological examinations and the level of inter-observer variation among methods [Table 3].

Table 3. Internal validity (methodological and parasitological) of included trials.

Sensitivity analysis

Three different methods were employed to perform sensitivity analysis of these trials. We first excluded the trial in which the parasitological method employed was not clearly described [45]. Second, the trials that utilized the most insensitive diagnostic methods, i.e. direct stool microscopy, alone were excluded [39], [40]. Finally, we excluded a trial that used the most sensitive parasitological methods (three methods at the same time) [41], and compared the results with the remaining trials which used two parasitological methods.

Data synthesis, statistical analysis

We identified eight randomized, controlled trials that reported data on the comparison of the effectiveness of albendazole with metronidazole in the treatment of giardiasis in humans. The inconsistency across trials was calculated using the I2 statistic; results range between 0% (i.e., no observed heterogeneity) and 100% [48]. High values reflect increasing heterogeneity. Publication bias was assessed by means of funnel plots [49]. Relative risks (RRs) were calculated for each study outcome separately based on information presented in articles (i.e. the percentage of people exhibiting parasitological cure in both groups relative to the percentage of people continuing to shed cysts during the follow up period); the pooled RRs and 95% confidence intervals (CIs) were estimated by using the inverse-variance random-effects method [50]. Although there is no standard description, an I2 statistic greater than 20% suggests heterogeneity while an I2 statistic greater than 50% usually is considered to represent significant heterogeneity [48]. The statistical package Review Manager Software 5 (Cochrane Collaboration, Oxford, UK) was used for analyzing the data.


Table 1 and Table 2 summarize the characteristics of the randomized clinical trails (RCTs) included in the meta-analysis. Studies were conducted in areas that are endemic for giardiasis in humans, including Iran [39], Turkey [40], [41], Mexico [42], [44], India [29], [45] and Bangladesh [43]. Only one study [43] was rated as having good methodological quality based on a Jadad score of 3 (see Table 3). However, because of the difficulty of comparing different treatment protocols, one would rarely expect to achieve a high Jadad score of 3 or greater. Only two studies [39], [43] had at least one blinded outcome measurement (parasitological cure); whereas the other 6 trials were open label randomized clinical trials (RCTs), allocating patients to albendazole and metronidazole groups randomly. Patients included in one of the groups in all trials were given albendazole. The dosages of albendazole ranged from 10 mg/kg sid for 5 days [41] to 400 mg/d for 5 days in most trials; lengths of therapy ranged from a single dose for 1 day to 5 days. Metronidazole dosage ranged from 22.5 mg/day [29] to 1500 mg/day [40], and the treatment course varied from 5 to 7 days. In six studies, subjects had symptomatic and/or asymptomatic giardiasis while the clinical status of patients in one study [45] was unclear. It is likely that the overwhelming majority, if not all, of the cases included in the study of Hall and Nahar [43] were asymptomatic cyst-passers, since the general population in an urban slum in Dhaka, Bangladesh was screened. The post-treatment follow-up differed across the studies from 10 days [39], [43] to 21 days [29], [42], [45]. Loss of follow-up did not occur in six studies whereas two articles [29], [39] reported withdrawals and/or dropouts. In one study [29], only 18/32 children in the albendazole group and 16/32 children in the metronidazole group finished the study, while in the other study, of 60 patients in each arm 15 from the albendazole group and 9 from the metronidazole group failed to complete the course of medication [39]. Side effects from metronidazole therapy did not appear to influence the treatment outcome, since low compliance in the latter study was reported to be due to difficulties in returning to the study clinic rather than to side effects of the treatments.

The included studies implemented different diagnostic procedures alone or in combination with other parasitological methods. As seen in Table 2, Yereli et al. [41] applied three different parasitological methods at the same time (a parasitological assessment score of 13 out of 15). Misra et al. [29], Romero-Cabello et al. [42], and Nahar and Hall [43] employed two different parasitological methods at the same time, Rodríguez-García et al. [44] used the Faust's concentration method whereas Alizadeh et al. [39] and Karabay et al. [40] utilized the least sensitive parasitological method, conventional direct stool microscopy, for measuring the outcomes. In all studies, the absence of detectable G. duodenalis trophozoites and/or cysts in the stool microscopy during the follow-up period was required to declare the patients cured; five studies measured the outcomes solely based on parasitological parameters [39], [40], [41], [43], [44], while three studies applied both parasitological and clinical parameters for measuring the outcomes [29], [42], [45].

Treatment effects were evaluated as relative risks (RR), estimates that were calculated for each study individually based on the incidence of undetectable infections among those taking metronidazole compared to the incidence of undetectable cases among those taking albendazole. Study-specific RRs were combined using a random-effects model. The study-specific RRs were weighted by the inverse of the sum of their variance and the estimated between-studies variance component [50]. This method calculates the mean difference between the treatment and control groups, with SEM for the difference. There was no statistically significant heterogeneity among these studies using the random effects model (χ2 = 11.91, 8 degrees of freedom, P = 0.16). An I2 of 33% in the current meta-analysis suggests moderate heterogeneity. Results demonstrated no differences between the effectiveness of albendazole compared with metronidazole for treatment of infections with G. duodenalis (RR, 0.97; 95% CI, 0.93 to 1.01). When analysis was restricted to trials with a Jadad score of less than 3 (seven trials, 617 patients), inconsistency between the trials was low (I2 = 0%), although the overall estimates remained almost constant (RR, 0.99; CI, 0.96 to 1.03). Individual analyses of the eight studies demonstrated that three studies [39], [41], [44], showed a relative risk of greater than 1 for being cured after albendazole therapy (Figure 2). These differences showed that albendazole produced more apparent cures compared with metronidazole. In one study [45], the relative risk was 1 indicating no differences between the effectiveness of albendazole and metronidazole. However, four studies [29], [40], [42], [43], showed a relative risk less than 1 (ranging from 0.89 to 0.96) indicating that metronidazole was more effective (Figure 2). As illustrated in figure 2, the 95% confidence intervals for these studies overlapped to a large degree, suggesting that albendazole and metronidazole are equally effective for treatment of giardiasis.

Figure 2. Forest plot showing the effects of albendazole and metronidazole on human giardiasis.

Relative risk was calculated for each study separately. n/N = number described as cured over number of participants completing study.

Further examination of the two-phase study carried out by Hall and Nahar [43] showed that by increasing the duration of therapy with albendazole from 400 mg/d for 3 days (in the first phase) to 400 mg/d for 5 days (in the second phase) the RR increased from 0.89 to 0.94. This suggests that when duration of treatment is similar there is less of a difference between albendazole and metronidazole therapy. Additionally, the efficacy of albendazole in the treatment of giardiasis increased in the second phase of the same study (94.1%) compared with the first phase of the trial (87.8%), implying the need for using albendazole for longer periods of time.

Publication bias and sensitivity analysis

Publication bias was examined using a funnel plot. Figure 3 plots the funnel plot of the treatment effects estimated from individual studies on the x-axis (RR) and the standard error of these estimates on y-axis (S.E [log RR]). This analysis shows that the included studies were almost evenly distributed around the vertical axis, providing no evidence of publication bias. To explore further the possibility of heterogeneity due to the use of different outcome measures, we confined our analysis to trials which used the least sensitive methods to detect parasites and then to those that used the most sensitive methods (three methods at the same time). Similarly, we performed an analysis restricted to those studies with clearly defined outcome measures. As seen in Table 4, the overall estimates were equal and the confidence intervals were comparable among these restricted data sets, as well as with the combined meta-analysis values.

Figure 3. Funnel plots of included studies.

The pooled estimate of log-RR for all trials is shown with a dashed vertical line.

Table 4. Sensitivity-analysis of the effect of the quality of methods implemented for the measurement of parasitological cure.

Adverse effects

In six studies, side effects related to therapy were absent or were less prominent in the patients receiving albendazole. Only in one study [43] were the reported side effects more evident in patients in the albendazole group compared with those in the metronidazole group (40 cases vs. 7 cases; P<0.005). Overall, metallic taste and anorexia were the most commonly observed side effects in patients treated with metronidazole, while loose stools and abdominal pain were more frequent among patients receiving albendazole. Most side effects were transient and no trials were discontinued because of severe adverse effects. In Yereli et al. [41], no side effects were reported in patients treated with either albendazole or metronidazole. The report by Rodríguez-García et al. [44] does not mention if treated children showed any side effects. In order to perform a safety analysis, the two latter studies were excluded from the analysis. Hall and Nahar [43] reported the adverse effects of a two-stage trial, and these were treated as a single trial. Considering all side effects together, 61 of 373 (16.3%) patients treated with albendazole and 82 of 371 (22.1%) of patients treated with metronidazole experienced at least a single side effect. The estimated summary RRs showed that individuals treated with albendazole had a lower risk of adverse effects (RR 0.36) compared with those who took metronidazole, but with a wide confidence interval (95% CI, 0.10, 1.34) that included the null value.


The major finding of this analysis is that when albendazole was given as a single dose of 400 mg/day for 5 days it was as effective as metronidazole in the treatment of giardiasis in humans. Additionally, albendazole had statistically the same safety profile as metronidazole.

Metronidazole has been widely used to treat giardiasis in humans [10], [38], [51], [52], [53], [54], and often causes side effects such as nausea, metallic taste, dizziness and headache [8]. In addition, this drug is a known mutagen in bacteria [55], [56], it is genotoxic to human cells [57], [58] and it has been shown to be carcinogenic in animal models [59], [60]. However, there is no evidence showing metronidazole is also carcinogenic in humans [60]. Typically, metronidazole is administered in doses of 250 mg 3 times a day for 5–7 days for adults and 15 mg/kg 3 times a day for 5–7 days in children. Some clinicians tend to use single-dose regimens, while others like to administer higher dosages for an extended period of time. The latter is problematic in developing countries, as medications are frequently purchased in quantities which represent less than a single day's dose and effective therapies of short duration are preferable [61]. The need for an extended period of time for the treatment of giardiasis again may in part explain the frequent side effects associated with metronidazole therapy. Extended treatment with albendazole also appears to be more effective than shorter duration protocols. However, the once per day regimen would still be preferable to the three times per day required for metronidazole therapy.

A further complication when using metronidazole therapy to treat giardiasis is that the consumption of alcohol should be avoided by patients during systemic metronidazole therapy and for at least 24 hours after completion of treatment [62], [63]. Taking metronidazole and alcohol may result, rarely, in a disulfiram-like reaction (nausea, vomiting, flushing, and tachycardia). It should be noted that the consumption of alcohol by patients was not monitored in any of the studies considered in the current meta-analysis. Alcohol uptake could potentially explain side effects in some patients receiving metronidazole. The lack of placebo-controlled trials makes it difficult to attribute the existence and severity of side effects to either of these two drugs. However, one study that did not meet our inclusion criteria suggested that patients receiving a placebo control presented with minimal side effects [10]. Together, these limitations can potentially restrict the use of metronidazole, in the treatment of giardiasis in humans.

In the trials included in the current meta-analysis, only one study [39] clearly described the inclusion of both adults and children (2–53 yr), while other studies exclusively included either only adults [40] or only children [29], [41], [42], [43], [44], [45]. The inclusion of different age-groups potentially allows us to assess the effectiveness of treatment and to ascertain the extent to which side effects occur in different age-groups. Similarly, including patients with diverse clinical presentations (i.e. asymptomatic, symptomatic; acute, subacute, chronic) in clinical trials could give us the opportunity to evaluate the effect(s) of a given chemotherapy agent/protocol on patients with different clinical manifestations. From the information presented in the articles, it seems that only three articles [41], [42], [44] included both symptomatic and asymptomatic patients, although the clinical status of patients who participated in the study of Hall and Nahar [43] and Dutta et al. [45] was not clear. Including patients from different age-groups and with different clinical presentations in future studies would allow investigators to analyze whether albendazole has a differential effect that correlates to the disease clinical profile and/or age of the patient.

Our analysis suggests that the study designs typically used for evaluating these drugs could be improved. Open-label trials may be suitable for comparing two extremely similar treatments to verify which one is more effective. Only Alizadeh et al. [39] and Hall and Nahar [43] used an adequate protocol for concealing the treatment protocol while determining the parasitological outcome. The six other trials either did not specify or were insufficient in using blinded observers to determine the outcome. Since albendazole and metronidazole may produce certain side effects specific to each drug and since these two drugs may be available in different forms, the use of homogenous therapy regimens and/or using blinded studies may be warranted in future clinical trials.

Several factors may influence the effectiveness of a particular therapy. Nutritional and physiological conditions such as pregnancy and immunodeficiency could potentially alter the effectiveness of a specific drug as shown for other parasitic diseases [64][67]. Individuals with “pre-existing” nutritional and physiological (pregnant women) complications were excluded in only two studies among those we have analyzed [40], [45]. Dutta et al. [45] excluded children having grade I and II malnutrition, patients with acute febrile illness and those on long term drug therapy; while Karabay et al. [40] excluded pregnant women and patients with fever from the study. In future studies, it would be desirable to include only patients with no known nutritional, physiological or immunological problems.

Resistance of G. duodenalis strains to metronidazole and other drugs has been reported both in vitro and in vivo [8], [68], [69]. Misra et al. [29] reported a 100% cure rate in groups treated with either metronidazole or albendazole, while the other seven reported an effectiveness of 72.7–100% for metronidazole and 77–97% for albendazole. At least part of the so-called “failure-to-treat” cases might be attributed to the presence of “drug-resistant” strains, a mechanism to which none of the studies referred as a potential reason for treatment failure. The use of different combinations of albendazole with other anti-parasitic agents in future studies may be desirable in order to minimize the risk of the emergence of drug-resistant strains. However, the design of placebo-controlled double blinded clinical trials may help us to better understand the most appropriate regimen(s) and the most suitable chemotherapy protocols.

Some limitations in the current analysis should be considered before making definitive conclusions. First, the small number of trials and patients included in the current analysis (8 studies, 900 patients) led to wide confidence intervals that rendered some of the results inconclusive [70]. Second, publication bias is constantly a potential pitfall in meta-analyses. While we did not try to trace unpublished data for the current meta-analysis, our analysis failed to detect any suggestion of such bias (Figure 3). Third, heterogeneity among studies is another potential limitation to our meta-analysis. It might be argued that differences in the methods used for measuring the outcome of treatment could result in differences in the reported parasitological cure rates, as some combined methods are more sensitive than others. As seen in Table 4, the effect sizes remained fairly constant in these analyses, suggesting that heterogeneity due to diverse outcome measures probably did not adversely affect our analyses. Performing repeated microscopy-based stool examinations on at least two consecutive occasions is sensitive enough to detect up to 95% of infections [71],[72]. This could potentially explain why we did not see any difference among studies employing diverse methods since all the studies required at least two consecutive negative stool examinations before considering the patients cured.

The high rate of side effects from metronidazole therapy for giardiasis, combined with the global emergence of resistant strains, led us to consider the effectiveness of alternative treatments. This meta-analysis revealed that albendazole cures Giardia infections with the same effectiveness as metronidazole. However, we were not able to show conclusively, due to limitations of the sample size, that its toxicity profile is more favorable than metronidazole. Therefore, we conclude that larger, double-masked, randomized controlled trials of albendazole and metronidazole with uniform outcome measures are needed to shed light on this important clinical question.

Author Contributions

Conceived and designed the experiments: SSM JMG CAL. Performed the experiments: SSM SMS. Analyzed the data: SSM JMG CAL SMS. Contributed reagents/materials/analysis tools: SSM. Wrote the paper: SSM SMS.


  1. 1. Adam RD (2001) Biology of Giardia labmlia. Clin Microbiol Rev 14: 447–475.
  2. 2. Farthing MJ (1994) Diarrhoeal disease: current concepts and future challenges. Pathogenesis of giardiasis. Trans R Soc Trop Med Hyg 3: 17–21.
  3. 3. Gillin FD, Reiner DS, McCaffery JM (1996) Cell biology of the primitive eukaryote Giardia lamblia. Annu Rev Microbiol 50: 679–705.
  4. 4. Flanagan PA (1992) Giardia–diagnosis, clinical course and epidemiology. A review. Epidemiol Infect 109: 1–22.
  5. 5. Wolfe MS (1992) Giardiasis. Clin Microbiol Rev 5: 93–100.
  6. 6. Kamda JD, Singer SM (2009) Phosphoinositide 3-kinase-dependent inhibition of dendritic cell interleukin-12 production by Giardia lamblia. Infect Immun 77: 685–693.
  7. 7. Isaac-Renton JL.Laboratory diagnosis of giardiasis. Clin Lab Med 11: 811–827.
  8. 8. Gardner TB, Hill DR (2001) Treatment of giardiasis. Clin Microbiol Rev 14: 114–128.
  9. 9. Sullivan PS, DuPont HL, Arafat RR, Thornton SA, Selwyn BJ, et al. (1989) Illness and reservoirs associated with Giardia lamblia infection in rural Egypt: the case against treatment in developing world environments of high endemicity. Am J Epidemiol 127: 1272–1281.
  10. 10. Saffar MJ, Qaffari J, Khalilian AR, Kosarian M (2005) Rapid reinfection by Giardia lamblia after treatment in a hyperendemic area: the case against treatment. East Mediterr Health J 11: 73–78.
  11. 11. Andersson T, Forssell J, Sterner G (1972) Outbreak of giardiasis: effect of a new antiflagellate drug, tinidazole. Br Med J 2: 449–451.
  12. 12. Jokipii L, Jokipii AM (1979) Single-dose metronidazole and tinidazole as therapy for giardiasis: success rates, side effects, and drug absorption and elimination. J Infect Dis 140: 984–988.
  13. 13. Johnson G (2009) STEPS New Drug Review: Tinidazole for trichomoniasis and bacterial vaginosis. Am Fam Phys 79: 102–103.
  14. 14. Bassily S, Farid Z, Mikhail JW, Kent DC, Lehman JS (1970) The treatment of Giardia lamblia infection with mepacrine, metronidazole and furazolidone. J Trop Med Hyg 73: 15–18.
  15. 15. Jokipii L, Jokipii AMM (1978) Comparison of four dosage schedules in the treatment of giardiasis with metronidazole. Infection 6: 92–94.
  16. 16. Kavousi S (1979) Giardiasis in infancy and childhood: a prospective study of 160 cases with comparison of quinacrine (Atabrine®) and metronidazole (Flagyl®). Am J Trop Med Hyg 28: 19–23.
  17. 17. Wright JM, Dunn LA, Upcroft P, Upcroft JA (2003) Efficacy of antigiardial drugs. Expert Opin Drug Saf 2: 529–541.
  18. 18. Selgrad M, Kandulski A, Malfertheiner P (2009) Helicobacter pylori: diagnosis and treatment. Curr Opin Gastroenterol 25: 549–556.
  19. 19. Lemée V, Zaharia I, Nevez G, Rabodonirina M, Brasseur P, et al. (2000) Metronidazole and albendazole susceptibility of 11 clinical isolates of Giardia duodenalis from France. J Antimicrob Chemother 46: 819–821.
  20. 20. Shepherd RW, Boreham PFL (1986) Recent advances in the diagnosis and management of giardiasis. Scand J Gastroenterol Suppl 169: 60–64.
  21. 21. Boreham PFL, Benrimoj S, Ong M, Craig M, Shepherd RW, et al. (1986) A compliance study in pediatrics patients receiving treatment for giardiasis. Aus J Hosp Pharm 16: 138–142.
  22. 22. Hemphill A, Müller J (2009) Alveolar and cystic echinococcosis: towards novel chemotherapeutical treatment options. J Helminthol 83: 99–111.
  23. 23. Carpio A (2002) Neurocysticercosis: an update. Lancet Infect Dis 2: 751–762.
  24. 24. Keiser J, Utzinger J (2008) Efficacy of current drugs against soil-transmitted helminth infections: systematic review and meta-analysis. JAMA 299: 1937–1948.
  25. 25. Bharti N, Husain K, Gonzalez Garza MT, Cruz-Vega DE, Castro-Garza J, et al. (2002) Synthesis and in vitro antiprotozoal activity of 5-nitrothiophene-2-carboxaldehyde thiosemicarbazone derivatives. Bioorg Med Chem Lett 12: 3475–3478.
  26. 26. Reynoldson JA, Thompson RC, Meloni BP (1991) In vivo efficacy of albendazole against Giardia duodenalis in mice. Parasitol Res 77: 325–328.
  27. 27. Cedillo-Rivera R, Muñoz O (1992) In vitro susceptibility of Giardia lamblia to albendazole, mebendazole and other chemotherapeutic agents. J Med Microbiol 37: 221–224.
  28. 28. Mank TG, Zaat JO (2001) Diagnostic advantages and therapeutic options for giardiasis. Expert Opin Investig Drugs 10: 1513–1519.
  29. 29. Misra PK, Kumar A, Agarwal V, Jagota SC (1995a) A comparative clinical trial of albendazole versus metronidazole in children with giardiasis. Indian Pediatr 32: 779–782.
  30. 30. Misra PK, Kumar A, Agarwal V, Jagota SC (1995b) A comparative clinical trial of albendazole versus metronidazole in giardiasis. Indian Pediatr 32: 291–294.
  31. 31. Meyer EK (1998) Adverse events associated with albendazole and other products used for treatment of giardiasis in dogs. J Am Vet Med Assoc 213: 44–46.
  32. 32. Bernal-Redondo R, Martínez-Méndez LG, Mendoza-Chavez A, Velasco-Perales D, Chavez-Munguia B (2004) Evaluation of the in vitro effect of albendazole, metronidazole and nitazoxanide on viability and structure of Giardia lamblia cysts. J Submicrosc Cytol Pathol 36: 241–245.
  33. 33. Reynoldson JA, Behnke JM, Gracey M, Horton RJ, Spargo R, et al. (1998) Efficacy of albendazole against Giardia and hookworm in a remote Aboriginal community in the north of Western Australia. Acta Trop 71: 27–44.
  34. 34. Pungpak S, Singhasivanon V, Bunnag D, Radomyos B, Nibaddhasopon P, et al. (1996) Albendazole as a treatment for Giardia infection. Ann Trop Med Parasitol 90: 563–565.
  35. 35. Baqai R, Zuberi SJ, Qureshi H, Ahmed W, Hafiz S (2001) Efficacy of albendazole in giardiasis. East Meditter Health J 7: 787–790.
  36. 36. Navarrete-Vázquez G, Yépez L, Hernández-Campos A, Tapia A, Hernández-Luis F, et al. (2003) Synthesis and antiparasitic activity of albendazole and mebendazole analogues. Bioorg Med Chem 11: 4615–4622.
  37. 37. Cacopardo B, Patamia I, Bonaccorso V, Di Paola O, Bonforte S, et al. (1995) Synergic effect of albendazole plus metronidazole association in the treatment of metronidazole-resistant giardiasis. Clin Ter 146: 761–767. [In Italian].
  38. 38. Hanevik K, Mørch K, Eide GE, Langeland N, Hausken T (2008) Effects of albendazole/metronidazole or tetracycline/folate treatments on persisting symptoms after Giardia infection: a randomized open clinical trial. Scand J Infect Dis 40: 517–522.
  39. 39. Alizadeh A, Ranjbar M, Kashani KM, Taheri MM, Bodaghi M (2006) Albendazole versus metronidazole in the treatment of patients with giardiasis in the Islamic Republic of Iran. East Meditter Health J 12: 548–554.
  40. 40. Karabay O, Tamer A, Gunduz H, Kayas D, Arinc H, et al. (2004) Albendazole versus metronidazole treatment of adult giardiasis: An open randomized clinical study. World J Gastroenterol 10: 1215–1217.
  41. 41. Yereli K, Balcioğlu IC, Ertan P, Limoncu E, Onağ A (2004) Albendazole as an alternative therapeutic agent for childhood giardiasis in Turkey. Clin Microbiol Infect 10: 527–529.
  42. 42. Romero-Cabello R, Robert L, Muñoz-García R, Tanaka J (1995) Randomized study comparing the safety and efficacy of albendazole and metronidazole in the treatment of giardiasis in children. Rev Latinoam Microbiol 37: 315–323. [In Spanish].
  43. 43. Hall A, Nahar Q (1993a, b) Albendazole as a treatment for infections with Giardia duodenalis in children in Bangladesh. Trans R Soc Trop Med Hyg 87: 84–86.
  44. 44. Rodríguez-García R, Aburto-Bandala M, Sánchez-Maldonado MI (1996) Effectiveness of albendazole in the treatment of giardiasis in children. Bol Med Hosp Infant Méx 53: 173–177. [In Spanish].
  45. 45. Dutta AK, Phadke MA, Bagade AC, Joshi V, Gazder A, et al. (1994) A randomised multicentre study to compare the safety and efficacy of albendazole and metronidazole in the treatment of giardiasis in children. Indian J Pediatr 61: 689–693.
  46. 46. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, et al. (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17: 1–12.
  47. 47. Zaat JO, Mank TG, Assendelft WJ (1997) A systematic review on the treatment of giardiasis. Trop Med Int Health 2: 63–82.
  48. 48. Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21: 1539–1558.
  49. 49. Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315: 629–634.
  50. 50. DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7: 177–188.
  51. 51. Jokipii L, Jokipii AM (1978) Comparison of four dosage schedules in the treatment of giardiasis with metronidazole. Infection 6: 92–94.
  52. 52. Jokipii L, Jokipii AM (1979) Single-dose metronidazole and tinidazole as therapy for giardiasis: success rates, side effects, and drug absorption and elimination. J Infect Dis 140: 984–988.
  53. 53. Rastegar-Lari A, Salek-Moghaddam A (1996) Single-dose secnidazole versus 10-day metronidazole therapy of giardiasis in Iranian children. J Trop Pediatr 42: 184–185.
  54. 54. Bulut BU, Gülnar SB, Aysev D (1996) Alternative treatment protocols in giardiasis: a pilot study. Scand J Infect Dis 28: 493–495.
  55. 55. Cantelli-Forti G, Aicardi G, Guerra MC, Barbaro AM, Biagi GL (1983) Mutagenicity of a series of 25 nitroimidazoles and two nitrothiazoles in Salmonella typhimurium. Teratog Carcinog Mutagen 3: 51–63.
  56. 56. De Méo M, Vanelle P, Bernadini E, Laget M, Maldonado J, et al. (1992) Evaluation of the mutagenic and genotoxic activities of 48 nitroimidazoles and related imidazole derivatives by the Ames test and the SOS chromotest. Environ Mol Mutagen 19: 167–181.
  57. 57. Reitz M, Rumpf M, Knitza R (1991) DNA single strand-breaks in lymphocytes after metronidazole therapy. Arzneimittelforschung 41: 155–156.
  58. 58. Elizondo G, Gonsebatt ME, Salazar AM, Lares I, Santiago P, et al. (1996) Genotoxic effects of metronidazole. Mutat Res 370: 75–80.
  59. 59. Krause JR, Ayuyang HQ, Ellis LD (1985) Occurrence of three cases of carcinoma in individuals with Crohn's disease treated with metronidazole. Am J Gastroenterol 80: 978–982.
  60. 60. Bendesky A, Menéndez D, Ostrosky-Wegman P (2002) Is metronidazole carcinogenic? Mutat Res 511: 133–144.
  61. 61. Hossain MM, Glass RI, Khan MR (1982) Antibiotic use in a rural community in Bangladesh. Int J Epidemiol 11: 402–405.
  62. 62. Tillonen J, Väkeväinen S, Salaspuro V, Zhang Y, Rautio M, et al. (2000) Metronidazole increases intracolonic but not peripheral blood acetaldehyde in chronic ethanol-treated rats. Alcohol Clin Exp Res 24: 570–575.
  63. 63. Jang GR, Harris RZ (2007) Drug interactions involving ethanol and alcoholic beverages. Expert Opin Drug Metab Toxicol 3: 719–731.
  64. 64. Lwin M, Targett GA, Doenhoff MG (1987) Reduced efficacy of chemotherapy of Plasmodium chabaudi in T cell-deprived mice. Trans R Soc Trop Med Hyg 81: 899–902.
  65. 65. Bjorkman A (1988) Interactions between chemotherapy and immunity to malaria. Prog Allergy 41: 331–356.
  66. 66. Mohan K, Sam HH, Stevenson MM (1999) Therapy with a combination of low doses of interleukin-12 and chloroquine completely cures blood-stage malaria, prevents severe anemia, and induces immunity to reinfection. Infect Immun 67: 513–519.
  67. 67. Cravo P, Culleton R, Hunt P, Walliker D, Mackinnon MJ (2001) Antimalarial drugs clear resistant parasites from partially immune hosts. Antimicrob Agents Chemother 45: 2897–2901.
  68. 68. Upcroft JA, Upcroft P (1993) Drug resistance and Giardia. Parasitol Today 9: 187–190.
  69. 69. Müller J, Ley S, Felger I, Hemphill A, Müller N (2008) Identification of differentially expressed genes in a Giardia lamblia WB C6 clone resistant to nitazoxanide and metronidazole. J Antimicrob Chemother 62: 72–82.
  70. 70. Matthaiou DK, Panos G, Adamidi ES, Falagas ME (2008) Albendazole versus praziquantel in the treatment of neurocysticercosis: A meta-analysis of comparative trials. PLoS Negl Trop Dis 2: e194.
  71. 71. Naik SR, Rau NR, Vinayak VK (1978) A comparative evaluation of three stool samples, jejunal aspirate and jejunal mucosal impression smears in the diagnosis of giardiasis. Ann Trop Med Parasitol 72: 491–492.
  72. 72. Gordts B, Hemelhof W, Van Tilborgh K, Retore P, Cadranal S, et al. (1985) Evaluation of a new method for routine in vitro cultivation of Giardia lamblia from human duodenal fluid. J Clin Microbiol 22: 702–704.